



Original Article
Virology



Dewormer drug fenbendazole has antiviral effects on BoHV-1 productive infection in cell cultures

Long Chang ^{1,2}, Liqian Zhu ^{1,2,*}

¹College of Veterinary Medicine, Yangzhou University, 48 Wenhui East Road, Yangzhou 225009, China

²Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, 48 Wenhui East Road, Yangzhou 225009, China

 OPEN ACCESS

Received: Apr 27, 2020

Revised: Jun 22, 2020

Accepted: Jul 21, 2020

*Corresponding author:

Liqian Zhu

College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, Jiangsu Province, China.

E-mail: lzhu3596@163.com

© 2020 The Korean Society of Veterinary Science

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Long Chang 

<https://orcid.org/0000-0003-3764-8073>

Liqian Zhu 

<https://orcid.org/0000-0002-9579-2252>

Funding

This research was supported by Chinese National Science Foundation Grant (Grant Nos. 31772743 and 31972655), and partially supported by A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and Key Laboratory for Preventive Research of Emerging Animal Diseases in Foshan University (KLPREAD201801-14).

Conflict of Interest

The authors declare no conflicts of interest.

ABSTRACT

Background: Fenbendazole, a dewormer drug, is used widely in the clinical treatment of parasite infections in animals. Recent studies have shown that fenbendazole has substantial effects on tumor growth, immune responses, and inflammatory responses, suggesting that fenbendazole is a pluripotent drug. Nevertheless, the antiviral effects have not been reported. Fenbendazole can disrupt microtubules, which are essential for multiple viruses infections, suggesting that fenbendazole might have antiviral effects.

Objectives: This study examined whether fenbendazole could inhibit bovine herpesvirus 1 (BoHV-1) productive infection in cell cultures.

Methods: The effects of fenbendazole on viral production, transcription of the immediate early (IE) genes, viron-associated protein expression, and the cellular signaling PLC- γ 1/Akt pathway were assessed using distinct methods.

Results: Fenbendazole could inhibit BoHV-1 productive infections significantly in MDBK cells in a dose-dependent manner. A time-of-addition assay indicated that fenbendazole affected both the early and late stages in the virus replication cycles. The transcription of IE genes, including BoHV-1 infected cell protein 0 (*bICP0*), *bICP4*, and *bICP22*, as well as the synthesis of viron-associated proteins, were disrupted differentially by the fenbendazole treatment. The treatment did not affect the cellular signaling pathway of PLC- γ 1/Akt, a known cascade playing important roles in virus infection.

Conclusions: Overall, fenbendazole has antiviral effects on BoHV-1 replication.

Keywords: Bovine herpesvirus 1; immediate early gene; fenbendazole; Akt

INTRODUCTION

Bovine herpesvirus 1 (BoHV-1), a member of the *alphaherpesvirus* subfamily, is an important pathogen causing a range of diseases in cattle, including pneumonia, conjunctivitis, and abortions [1]. Generally, the erosion of mucus and immune suppression due to virus infections may lead to secondary infections by diverse pathogens, resulting in life-threatening pneumonia known as bovine respiratory disease complex (BRDC) [2-4]. BRDC is one of the most important diseases in cattle of all ages and breeds [5,6], and exerts

Author Contributions

Conceptualization: Zhu L; Formal analysis: Zhu L, Chang L; Funding acquisition: Zhu L; Investigation: Chang L; Methodology: Zhu L, Chang L; Project administration: Zhu L; Resources: Zhu L; Software: Zhu L; Supervision: Zhu L; Validation: Zhu L, Chang L; Visualization: Chang L; Writing - original draft: Zhu L; Writing - review & editing: Zhu L.

considerable economic loss on the cattle industry worldwide. BRDC was reported to cost the US cattle industry approximately 3 billion dollars annually [7].

Fenbendazole ([5-(phenylthio)-1*H*-benzimidazol-2-yl] carbamic acid methyl ester) is used widely for the treatment of pinworms, helminths, and a variety of other parasitic infections in laboratory animals, livestock, companion animals, and humans [8,9]. Recent studies extended its spectrum of pharmacological effects, and gradually revealed previously unrecognized functions. For example, fenbendazole was recently reported to have anticancer effects by affecting the function of proteasome and microtubules, as well as glucose uptake [9-11]. Fenbendazole treatment could improve the functional recovery of a traumatic spinal cord injury by regulating the function of lymphocytes and the inflammatory response [12]. Fenbendazole can regulate the function of the mitochondria and the cellular immune responses of peripheral blood lymphocytes by reducing the production of inflammatory cytokines, such as IFN- γ , TNF- α , and IL-1 β [13,14]. Fenbendazole disrupts the gut microbiota of Amur tiger [15], indicating that it may affect the growth of bacteria. On the other hand, it is unclear if it possesses antiviral effects. Importantly, a fenbendazole treatment has several effects on cellular signaling transduction, such as the Akt and MAPK pathways in porcine trophectoderm [14]. Because both Akt and MAPK pathways are involved in BoHV-1 replication [16-18], it was hypothesized that fenbendazole might inhibit BoHV-1 replication.

This study examined whether fenbendazole affects BoHV-1 productive infections in cell cultures. A fenbendazole treatment reduced virus production by affecting the immediate early (IE) gene transcription and the synthesis of viron-associated proteins differentially. This is the first report showing that fenbendazole has antiviral effects.

MATERIALS AND METHODS

Viruses and cells

MDBK cells were maintained in DMEM (Gibco BRL) supplemented with 10% horse serum (Solarbio, cat# S9050). BoHV-1, NJ-16-1 isolated from bovine semen samples [19], was propagated in MDBK cells. Aliquots of virus stocks with a titer of 6.5×10^6 pfu/mL were stored at -70°C until use.

Chemicals and antibodies

In this study, the following antibodies and chemicals were used, including fenbendazole (MedChemExpress, cat# HY-B0413). The antibodies against phospho-Akt(p-Akt) (S473) (Cell Signaling Technology; cat# 9271), Akt (Cell Signaling Technology; cat # 9272), PLC- γ 1 (Cell Signaling Technology, cat# 2822S), p-PLC- γ 1(Ser1248) (Cell Signaling Technology, cat# 8713), GAPDH (Cell Signaling Technology, cat# 2118), and β -Actin (Cell Signaling Technology; cat# 4970) were used. Goat anti-BoHV-1 serum was purchased from VMDR Inc, Gandhinagar, India [20PAB-IBR]. HRP-(horseradish peroxidase-) conjugated goat anti-mouse IgG (Cell Signaling Technology, cat# 7076), HRP-goat anti-rabbit IgG (Cell Signaling Technology, cat# 7074), and HRP-donkey anti-goat IgG H&L (Abcam, ca# ab97110).

BoHV-1 VP16 antibody (1:2,000) was kindly provided by Prof. Vikram Misra at the University of Saskatchewan [20].

Antiviral effects assay

MDBK cells of confluent in 24-well plates were pretreated for one hour with either DMSO or fenbendazole (20 and 80 nM), respectively. The cells were then infected with BoHV-1 (MOI = 1) along with a chemical treatment. Two hours (h) after infection, the cells were washed three times with PBS (PH, 7.4) and replaced with fresh DMEM medium containing either DMSO or fenbendazole. The cell cultures were collected after infection for 24 h. After frozen-thawing twice, the cell cultures were clarified by centrifugation at 13,000 rpm for 5 min at 4°C. The virus titers in the supernatant were determined in the MDBK cells, with results expressed as TCID₅₀/mL calculated using the Reed-Muench calculation method.

Quantification of viral IE mRNA by qRT-PCR

The confluent MDBK cells in 60 mm dishes, which were pretreated with either DMSO or fenbendazole at a concentration of 20 nM, were infected with BoHV-1 (MOI = 1). After infection for 2 h, the cells were washed three times and the medium was replaced with fresh medium. Throughout infection, the cells were treated with either DMSO or fenbendazole. At 2 and 4 h post-infection (hpi), the cells were washed three times with PBS, and the total RNA was purified with TRIzol LS Reagent (Ambion, Cat#: 10296010) according to the manufacturer's instruction. Freshly prepared RNA (1 µg) was used as a template for the synthesis of the first-strand cDNA with commercial random hexamer primers for viral mRNA detection using a ThermoScript RT-PCR system Kit (Invitrogen, catalogue #11146-024). The cDNA products were used as templates for qPCR to measure the mRNA levels of viral IE genes, including BoHV-1 infected cell protein 0 (bICP0), bICP4, and bICP22 as well as cellular gene glyceraldehyde-3-phosphate *dehydrogenase* (*GAPDH*) with the specific primers as described previously in the reference [21]. *GAPDH* mRNA was used as an internal control to normalize gene expression. The data was analyzed using the equation $2^{-\Delta\Delta CT}$ method.

Western blotting analysis

MDBK cells in 60 mm dishes pretreated with either DMSO control or fenbendazole for one hour were mock-infected or infected with BoHV-1 (MOI = 1) for 12 and 24 h, respectively. Throughout the infection, the cells were treated with DMSO and fenbendazole at the indicated concentrations, respectively. The cells were collected, and cell lysates were prepared using RIPA buffer (1 × PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail. The clarified cell lysates through centrifugation at 13,000 rpm for 10 min were mixed with 4 X SDS-PAGE loading buffer, boiled for 10 min in a water bath, and subjected to Western blotting analysis using the designated antibodies. Either β-Actin or GAPDH was probed as the protein loading control.

RESULTS

Fenbendazole reduced BoHV-1 productive infection in cell cultures

The cytotoxicity of fenbendazole was initially examined on MDBK cells to determine if it had inhibitory effects on BoHV-1 productive infections. Based on a preliminary study, fenbendazole at a concentration of 80 nM for 24 h did not show apparent cytotoxicity to MDBK cells according to a Trypan-blue exclusion test, as described elsewhere [22] (**Fig. 1A**). Subsequently, the antiviral effects of fenbendazole at various concentrations (80 and 20 nM) were evaluated. The virus-infected cells were treated with fenbendazole throughout the infection, along with pretreatment for 1 h, as shown in the diagram (**Fig. 1B**, upper panel). Compared to the DMSO control, the presence of fenbendazole at a concentration of 20 and




Fig. 1. Fenbendazole could significantly inhibit BoHV-1 infections in MDBK cells. (A) MDBK cells were treated with fenbendazole for 24 h. The cytotoxicity of fenbendazole on the cell cultures was determined using a Trypan-blue exclusion test. (B-D) Diagrams showing different experimental conditions for the individual assays. DMSO, the treatment with DMSO for various durations of time during virus infection. Fen, the treatment for various durations of time during virus infection (upper panels). After infection for 24 h by either DMSO control or fenbendazole, the virus titer in the cell cultures was determined in MDBK cells (lower panels). Data shown are means ± SD of three independent experiments. Statistical analyses were performed using Student's *t*-test (**P* < 0.05). ns, not significant; hpi, hours post-infection.

80 nM reduced virus production by approximately 1.5- and 2.1-log, respectively (**Fig. 1B**, lower panel). This suggests that fenbendazole could inhibit BoHV-1 replication in cell cultures in a dose-dependent manner. Because fenbendazole at lower concentrations of 20 nM also showed inhibitory effects, the concentration of 20 nM was applied in the following studies.

A time-of-addition assay was performed to point which step(s) of the BoHV-1 replication cycles were affected by fenbendazole. Fenbendazole at a concentration of 20 nM was added to the virus-infected cell cultures at 0, 1, and 4 hpi, respectively, as shown in the diagram (**Fig. 1C**, upper panel). Compared to the DMSO control, the fenbendazole treatment starting from 0 hpi reduced the virus titer by approximately 1.2-log (**Fig. 1C**, lower panel). When fenbendazole was applied from 1 and 4 hpi, the virus yields were reduced consistently by ~0.7 log relative to the DMSO control (**Fig. 1C**, lower panel). These results suggest that both the early and late stages in the virus replication cycles were potentially affected by fenbendazole.

When fenbendazole was present in the virus-infected cells for one hour starting from 0 hpi, as shown in the diagram (**Fig. 1D**, upper panel), the virus titer was reduced by ~0.8 log compared to that of the DMSO control (**Fig. 1D**, lower panel). This further confirmed that fenbendazole affects virus replication at the early stages of infection.

Fenbendazole affected BoHV-1 IE transcription

The transcription of BoHV-1 IE genes starts at the early stages of infection, which is essential for a virus-productive infection. Here, the effects of fenbendazole on IE gene transcription were detected. The virus-infected cells were infected for 2 and 4 h together with the fenbendazole treatment at 20 nM. The levels of *bICP0*, *bICP4*, and *bICP22* mRNA were then detected by qRT-PCR. As a result, in the presence of fenbendazole, the mRNA levels of all the IE genes detected were consistently lower at 2 hpi, which were decreased by ~ 50% relative to the DMSO control (**Fig. 2**). At 4 hpi, compared to the mock-treated control, the *bICP0* mRNA


Fenbendazole has antiviral effects on BoHV-1 infection

Fig. 2. Fenbendazole affected viral IE transcription. MDBK cells were infected with BoHV-1 (MOI = 1) along with the treatment of fenbendazole or DMSO control plus a pretreatment for 1 h. At 2 and 4 hpi, the total RNA was purified, and the levels of viral mRNA of *bICP0* (A), *bICP4* (B), and *bICP22* (C) were detected with qRT-PCR. The data shown are the means \pm SD of three independent experiments. Statistical analyses were performed using Student's *t*-test (* P < 0.05; ** P < 0.01). ns, not significant; hpi, hours post-infection.

levels were not affected by fenbendazole (**Fig. 2A**). The *bICP4* mRNA levels significantly decreased to ~26% (**Fig. 2B**), while the *bICP22* mRNA levels were increased approximately 6-fold (**Fig. 2C**). These results suggest that fenbendazole affects the transcription of these IE genes in a distinct manner, which corroborates the findings that fenbendazole can inhibit BoHV-1 infections at the early stages in the time-of-addition assay (**Fig. 1C and D**).

Fenbendazole affected the expression of virion-associated proteins

Because fenbendazole differentially affected viral IE transcription (**Fig. 2**), this study examined whether the expression of virion-associated proteins in the cell culture was affected. MDBK cells were infected with BoHV-1 for 12 and 24 h and treated with either DMSO or fenbendazole (20 nM) during the infection. The virion-associated proteins were detected by Western blot analysis using an antibody against BoHV-1 virion, as described elsewhere [21]. As a result, four molecules arbitrarily denoted by α , β , γ , and ϵ , with distinct molecular weights ranging from 40 to 130 kDa could be detected clearly from the virus-infected cells at 24 hpi (**Fig. 3A**, right panel). The α and β proteins were readily detected at 12 hpi (**Fig. 3A**, left panel). GAPDH protein was probed in the same membrane to indicate the protein loading control accurately (**Fig. 3A**). Quantitative analysis indicated that α protein expression was not affected by fenbendazole at 12 hpi (**Fig. 3B**), but it was reduced by approximately 50% relative to the mock-treated control after infection for 24 h (**Fig. 3C**). The β protein levels were reduced to approximately 40% by fenbendazole relative to that in the mock-treated control at 12 hpi (**Fig. 3B**), but no inhibitory effect was observed at 24 hpi (**Fig. 3C**). At 24 hpi, following the fenbendazole treatment, the ϵ protein levels were ~63.1% compared to that in the mock-treated control, while γ protein expression was unaffected. Using a virus tegument protein VP16 specific antibody, VP16 protein expression was reduced significantly by fenbendazole at 12 hpi, which was reduced to approximately 45.5% compared to that of the control. After infection for 24 h, VP16 expression was unaffected by fenbendazole (**Fig. 3D-E**). Overall, the expression of virion-associated proteins, such as α , β , ϵ , and VP16 but not γ was affected differentially by fenbendazole. This shows that it has inhibitory effects on virus productive infection at the late stages in a time-of-addition assay (**Fig. 1C**).

Fenbendazole had no effects on the PLC- γ 1/Akt cascade stimulated by BoHV-1 infection

Fenbendazole broadly affects the cellular signaling transduction, such as Akt and MAPK pathways in porcine trophectoderm [14]. A BoHV-1 infection stimulates the PLC- γ 1/Akt cascade to facilitate virus-productive infection in cell cultures [17,23]. Here, we explored the




Fig. 3. Effects of Fenbendazole on the expression of virion-associated proteins. (A, D) MDBK cells were infected with BoHV-1 at an MOI of 1 for 12 and 24 h, in the presence of fenbendazole or DMSO control throughout infection plus a pretreatment for 1 h. The cell lysates were then prepared for Western blots to detect virion-associated proteins using a commercial anti-BoHV-1 serum (VMDR Inc, cat# P110325-001) (A) or VP16 specific antibody (D). Given bands were denoted with α , β , γ , and ϵ . (B, C, and E) The relative band intensity was analyzed with software image J, and each analysis was compared with that of uninfected control, which was arbitrarily set to one. The data shown are the means \pm SD of three independent experiments. Statistical analyses were performed using Student's *t*-test (**P* < 0.05). ns, not significant; hpi, hours post-infection.

effects of fenbendazole on the LC- γ 1/Akt cascade in MDBK cells in a context with or without BoHV-1 infection. The phosphorylation of PLC- γ 1 at site S1248 and Akt at site S473 correlated well with the activation of the individual protein, respectively. Surprisingly, the inhibitory effects on the phosphorylation of either PLC- γ 1 (Fig. 4A) or Akt (Fig. 4B) stimulated by a BoHV-1 infection were not observed after the fenbendazole treatment. In addition, in the context without infection, fenbendazole had no effects on the activation of either PLC- γ 1 or Akt in MDBK cells (Fig. 4). As expected, the vehicle control, DMSO, had no effects on the phosphorylation of both PLC- γ 1 and Akt in the context with or without a BoHV-1 infection (Fig. 4C), excluding the possible interruption by the solvent DMSO. These results suggest




Fig. 4. Fenbendazole did not affect the PLC- γ 1/Akt cascade stimulated by the BoHV-1 infection. (A, B) MDBK cells were infected with BoHV-1 (MOI = 1) for 24 h. Throughout the infection, the cells were treated with fenbendazole at various concentrations plus a pretreatment of 1 h. The cell lysates were prepared and subjected to Western blots to detect the variation of PLC- γ 1(S1248) and PLC- γ 1 (A), p-Akt(S473) and Akt (B), respectively. (C) MDBK cells pretreated with or without the vehicle control DMSO for 1 h were infected with BoHV-1 (MOI = 1) together with or without DMSO for 24 h. The cell lysates were collected, and protein levels of both PLC- γ 1(S1248) and p-Akt(S473) were detected by using Western blots. β -Actin was detected and used as a protein loading control. Data shown are representative results of two independent experiments.

that the inhibitory effects of fenbendazole on BoHV-1 infection do not rely on blocking the PLC- γ 1/Akt cascade essential for the virus infection.

DISCUSSION

Fenbendazole is an anti-parasite medicine approved by FDA that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, and seals. The drug can affect many gastrointestinal parasites, such as giardia, roundworms, hookworms, whipworms, and pinworms. Recently, several studies have indicated that fenbendazole is a promising candidate for the treatment of multiple cancers [9,10,24], providing insight on the pharmacological effects of fenbendazole. This study showed that fenbendazole has antiviral effects that can inhibit BoHV-1 productive infection in cell cultures, which would extend its pharmacological effects further.

Fenbendazole could physically associate with the cytoskeletal protein tubulin and disrupt the microtubule structure, a potential mechanism to kill parasites and tumors [9,10,25]. Previous studies reported that microtubules play critical roles in the replication cycles of multiple viruses, including human immunodeficiency virus type 1 (HIV-1), vaccinia virus, rabies virus, and herpes simplex virus 1 (HSV-1) [26-32]. HSV-1 virions consist of four structural components: DNA, capsid, tegument, and envelope [33]. Upon HSV-1 infection, the cellular microtubules are reorganized and partially mediated by the viral regulatory protein ICPO [30,34,35]. The incoming cytosolic capsids and tegument protein VP22 are transported along the microtubules to the nucleus [30,35-37]. Both BoHV-1 and HSV-1 belong to the *alpha*herpesvirus subfamily, and they generally share many biological features. The requirement of microtubules might also be applied to BoHV-1 productive infections. Thus, fenbendazole may inhibit BoHV-1 replication because of its strong capacity to disrupt microtubules.

During productive infection, the BoHV-1 genes are transcribed in an ordered cascade of immediate-early (IE), early (E), and late (L) genes [38], regulated by the viral and cellular transcriptional machinery. This study found that fenbendazole treatment had differential effects on the transcription of IE genes, including *bICPO*, *bICP4*, and *bICP22* (**Fig. 2**), as well as the protein expression of various viron-associated proteins (**Fig. 3**). These results are consistent with the findings that fenbendazole could broadly affect the early and late stages of a virus infection in a time-of-addition assay (**Fig. 1D-G**). The differential effects on viral gene transcription and protein expression are also in line with its antiviral activities.

Interestingly, this study found that fenbendazole decreased *bICP22* transcription at 2 hpi, but it was increased at four hpi. A similar phenomenon in other chemicals has been reported, e.g., HMGA1-specific inhibitor netropsin could inhibit BoHV-1 replication. The treatment with netropsin leads to the decreased transcription of *bICPO* and *bICP22*, but increased transcription of *bICP4* at 16 hpi [21]. Though cycloheximide could inhibit HSV-1 replication HSV-1 IE gene *ICPO* expression was enhanced by cycloheximide treatment [39]. Therefore, an antiviral compound, such as fenbendazole, may also have the capacity to upregulate the transcription of the given viral genes.

The Akt signaling pathway is activated by a BoHV-1 infection, which in turn plays critical roles in the virus productive infection in MDBK cells [16-18]. Fenbendazole was reported to affect Akt cellular signaling transduction in the porcine trophectoderm [14]. The present data indicated that Akt phosphorylation was not affected by fenbendazole with or without a

virus infection (**Fig. 4**). Of note, the bovine kidney cell line, MDBK, has different origins and biological features from the porcine trophectoderm, which may account for this discrepancy. Nevertheless, the data suggest that the antiviral activities of fenbendazole in MDBK cells were not depending on affecting Akt signaling.

In summary, the widely used dewormer, fenbendazole, can inhibit BoHV-1 replication by differentially affecting viral IE transcription and viron-associated protein synthesis. This is a novel finding on the pharmacological effects of fenbendazole.

REFERENCES

1. Tikoo SK, Campos M, Babiuk LA. Bovine herpesvirus 1 (BHV-1): biology, pathogenesis, and control. *Adv Virus Res.* 1995;45:191-223.
[PUBMED](#) | [CROSSREF](#)
2. Yates WD, Babiuk LA, Jericho KW. Viral-bacterial pneumonia in calves: duration of the interaction between bovine herpesvirus 1 and *Pasteurella haemolytica*. *Can J Comp Med.* 1983;47(3):257-264.
[PUBMED](#)
3. Hodgson PD, Aich P, Manuja A, Hokamp K, Roche FM, Brinkman FS, et al. Effect of stress on viral-bacterial synergy in bovine respiratory disease: novel mechanisms to regulate inflammation. *Comp Funct Genomics.* 2005;6(4):244-250.
[PUBMED](#) | [CROSSREF](#)
4. Jones C, Chowdhury S. Bovine herpesvirus type 1 (BHV-1) is an important cofactor in the bovine respiratory disease complex. *Vet Clin North Am Food Anim Pract.* 2010;26(2):303-321.
[PUBMED](#) | [CROSSREF](#)
5. Neibergs HL, Seabury CM, Wojtowicz AJ, Wang Z, Scraggs E, Kiser JN, et al. Susceptibility loci revealed for bovine respiratory disease complex in pre-weaned holstein calves. *BMC Genomics.* 2014;15(1):1164.
[PUBMED](#) | [CROSSREF](#)
6. Fulton RW, d'Offay JM, Landis C, Miles DG, Smith RA, Saliki JT, et al. Detection and characterization of viruses as field and vaccine strains in feedlot cattle with bovine respiratory disease. *Vaccine.* 2016;34(30):3478-3492.
[PUBMED](#) | [CROSSREF](#)
7. Jones C, Chowdhury S. A review of the biology of bovine herpesvirus type 1 (BHV-1), its role as a cofactor in the bovine respiratory disease complex and development of improved vaccines. *Anim Health Res Rev.* 2007;8(2):187-205.
[PUBMED](#) | [CROSSREF](#)
8. Villar D, Cray C, Zaias J, Altman NH. Biologic effects of fenbendazole in rats and mice: a review. *J Am Assoc Lab Anim Sci.* 2007;46(6):8-15.
[PUBMED](#)
9. Duan Q, Liu Y, Rockwell S. Fenbendazole as a potential anticancer drug. *Anticancer Res.* 2013;33(2):355-362.
[PUBMED](#)
10. Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. *Sci Rep.* 2018;8(1):11926.
[PUBMED](#) | [CROSSREF](#)
11. Lai SR, Castello SA, Robinson AC, Koehler JW. In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells. *Vet Comp Oncol.* 2017;15(4):1445-1454.
[PUBMED](#) | [CROSSREF](#)
12. Yu CG, Singh R, Crowds C, Raza K, Kincer J, Geddes JW. Fenbendazole improves pathological and functional recovery following traumatic spinal cord injury. *Neuroscience.* 2014;256:163-169.
[PUBMED](#) | [CROSSREF](#)
13. Nehete PN, Wilkerson G, Nehete BP, Chitta S, Ruiz JC, Scholtzova H, et al. Cellular immune responses in peripheral blood lymphocytes of *Giardia* infected squirrel monkey (*Saimiri boliviensis boliviensis*) treated with Fenbendazole. *PLoS One.* 2018;13(11):e0198497.
[PUBMED](#) | [CROSSREF](#)
14. Park H, Lim W, You S, Song G. Fenbendazole induces apoptosis of porcine uterine luminal epithelial and trophoblast cells during early pregnancy. *Sci Total Environ.* 2019;681:28-38.
[PUBMED](#) | [CROSSREF](#)

15. He F, Zhai J, Zhang L, Liu D, Ma Y, Rong K, et al. Variations in gut microbiota and fecal metabolic phenotype associated with Fenbendazole and Ivermectin Tablets by 16S rRNA gene sequencing and LC/MS-based metabolomics in Amur tiger. *Biochem Biophys Res Commun*. 2018;499(3):447-453.
[PUBMED](#) | [CROSSREF](#)
16. Zhu L, Yuan C, Huang L, Ding X, Wang J, Zhang D, et al. The activation of p38MAPK and JNK pathways in bovine herpesvirus 1 infected MDBK cells. *Vet Res (Faisalabad)*. 2016;47(1):91.
[PUBMED](#) | [CROSSREF](#)
17. Zhu L, Ding X, Zhu X, Meng S, Wang J, Zhou H, et al. Biphasic activation of PI3K/Akt and MAPK/Erk1/2 signaling pathways in bovine herpesvirus type 1 infection of MDBK cells. *Vet Res (Faisalabad)*. 2011;42(1):57.
[PUBMED](#) | [CROSSREF](#)
18. Zhu L, Thompson J, Ma F, Eudy J, Jones C. Effects of the synthetic corticosteroid dexamethasone on bovine herpesvirus 1 productive infection. *Virology*. 2017;505:71-79.
[PUBMED](#) | [CROSSREF](#)
19. Zhu L, Yu Y, Jiang X, Yuan W, Zhu G. First report of bovine herpesvirus 1 isolation from bull semen samples in China. *Acta Virol*. 2017;61(4):483-486.
[PUBMED](#) | [CROSSREF](#)
20. Misra V, Bratanich AC, Carpenter D, O'Hare P. Protein and DNA elements involved in transactivation of the promoter of the bovine herpesvirus (BHV) 1 IE-1 transcription unit by the BHV alpha gene trans-inducing factor. *J Virol*. 1994;68(8):4898-4909.
[PUBMED](#) | [CROSSREF](#)
21. Zhu L, Jones C. The high mobility group AT-hook 1 protein stimulates bovine herpesvirus 1 productive infection. *Virus Res*. 2017;238:236-242.
[PUBMED](#) | [CROSSREF](#)
22. Fiorito F, Marfè G, De Blasio E, Granato GE, Tafani M, De Martino L, et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin regulates bovine herpesvirus type 1 induced apoptosis by modulating Bcl-2 family members. *Apoptosis*. 2008;13(10):1243-1252.
[PUBMED](#) | [CROSSREF](#)
23. Zhu L, Yuan C, Ding X, Jones C, Zhu G. The role of phospholipase C signaling in bovine herpesvirus 1 infection. *Vet Res (Faisalabad)*. 2017;48(1):45.
[PUBMED](#) | [CROSSREF](#)
24. Gao P, Dang CV, Watson J. Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. *J Am Assoc Lab Anim Sci*. 2008;47(6):37-40.
[PUBMED](#)
25. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. *Int J Parasitol*. 1988;18(7):885-936.
[PUBMED](#) | [CROSSREF](#)
26. Zan J, Liu S, Sun DN, Mo KK, Yan Y, Liu J, et al. Rabies virus infection induces microtubule depolymerization to facilitate viral RNA synthesis by upregulating HDAC6. *Front Cell Infect Microbiol*. 2017;7:146.
[PUBMED](#) | [CROSSREF](#)
27. Fernandez J, Portilho DM, Danckaert A, Munier S, Becker A, Roux P, et al. Microtubule-associated proteins 1 (MAP1) promote human immunodeficiency virus type 1 (HIV-1) intracytoplasmic routing to the nucleus. *J Biol Chem*. 2015;290(8):4631-4646.
[PUBMED](#) | [CROSSREF](#)
28. Naghavi MH, Walsh D. Microtubule Regulation and Function during Virus Infection. *J Virol*. 2017;91(16):e00538-17.
[PUBMED](#) | [CROSSREF](#)
29. Niehl A, Peña EJ, Amari K, Heinlein M. Microtubules in viral replication and transport. *Plant J*. 2013;75(2):290-308.
[PUBMED](#) | [CROSSREF](#)
30. Kotsakis A, Pomeranz LE, Blouin A, Blaho JA. Microtubule reorganization during herpes simplex virus type 1 infection facilitates the nuclear localization of VP22, a major virion tegument protein. *J Virol*. 2001;75(18):8697-8711.
[PUBMED](#) | [CROSSREF](#)
31. Padeloup D, McElwee M, Beilstein F, Labetoulle M, Rixon FJ. Herpesvirus tegument protein pUL37 interacts with dystonin/BPAG1 to promote capsid transport on microtubules during egress. *J Virol*. 2013;87(5):2857-2867.
[PUBMED](#) | [CROSSREF](#)

32. Sanderson CM, Hollinshead M, Smith GL. The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. *J Gen Virol.* 2000;81(Pt 1):47-58.
[PUBMED](#) | [CROSSREF](#)
33. Zhou ZH, Dougherty M, Jakana J, He J, Rixon FJ, Chiu W. Seeing the herpesvirus capsid at 8.5 Å. *Science.* 2000;288(5467):877-880.
[PUBMED](#) | [CROSSREF](#)
34. Liu M, Schmidt EE, Halford WP. ICP0 dismantles microtubule networks in herpes simplex virus-infected cells. *PLoS One.* 2010;5(6):e10975.
[PUBMED](#) | [CROSSREF](#)
35. Döhner K, Wolfstein A, Prank U, Echeverri C, Dujardin D, Vallee R, et al. Function of dynein and dynactin in herpes simplex virus capsid transport. *Mol Biol Cell.* 2002;13(8):2795-2809.
[PUBMED](#) | [CROSSREF](#)
36. Padeloup D, Labetoulle M, Rixon FJ. Differing effects of herpes simplex virus 1 and pseudorabies virus infections on centrosomal function. *J Virol.* 2013;87(12):7102-7112.
[PUBMED](#) | [CROSSREF](#)
37. Zhong M, Zheng K, Chen M, Xiang Y, Jin F, Ma K, et al. Heat-shock protein 90 promotes nuclear transport of herpes simplex virus 1 capsid protein by interacting with acetylated tubulin. *PLoS One.* 2014;9(6):e99425.
[PUBMED](#) | [CROSSREF](#)
38. Jones C. Bovine herpesvirus 1 counteracts immune responses and immune-surveillance to enhance pathogenesis and virus transmission. *Front Immunol.* 2019;10:1008.
[PUBMED](#) | [CROSSREF](#)
39. Preston CM, Rinaldi A, Nicholl MJ. Herpes simplex virus type 1 immediate early gene expression is stimulated by inhibition of protein synthesis. *J Gen Virol.* 1998;79(Pt 1):117-124.
[PUBMED](#) | [CROSSREF](#)